ARCHIVES

NCI Places Hold On Genentech Drug Trials, Citing Disagreement Over Intellectual Property Provisions.

This article is from The Cancer Letter archive.

Vol. 36 No. 09 | March 12, 2010

Download PDF Visit The Full Archive

Related Articles

FDA Accepts DCT Board’s Criteria For Approval Of New Drugs, Explains Plan for Early Action

February 17, 1989

NCI Critics Take Their Best Shots, Seek New Emphasis On Prevention At Kennedy Hearings

March 16, 1979

NCAB Removes Its Restrictions On PDQ Access, Permits NCI Staff To Decide

February 7, 1986

Blood Vessel Growth Inhibitor May Be Tested Against KS

August 16, 1991

Groups Advise NCI On “Investment Opportunities”

June 28, 1996

Whole Brain Radiation Raises Risk Of Memory Problems

September 26, 2008